2 completed, 1 recruiting. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Recruiting 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow Hemosiderosis: new trials by email Literature Review of Hemosiderosis trials Research Report on Hemosiderosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Leflunomide for Idiopathic Pulmonary Hemosiderosis in Children Leflunomide, Steroid Drug - Idiopathic Pulmonary Hemosiderosis, Leflunomide | Phase 1 / Phase 2 | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 34 | 2023-06-01 | 2023-07-10 |
| Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Rare Chronic Anemia Patients Deferasirox - Anemia, Hemosiderosis | Phase 2 | Completed | Novartis Pharmaceuticals | 184 | 2004-03-01 | 2011-05-09 |
| Safety of ICL670 vs. Deferoxamine in Sickle Cell Disease Patients With Iron Overload Due to Blood Transfusions ICL670, deferoxamine - Anemia, Sickle Cell | Phase 2 | Completed | Novartis Pharmaceuticals | 195 | 2003-05-01 | 2017-08-22 |
Iron Overload (2) · Anemia (1) · Anemia, Sickle Cell (1) · Hemosiderosis, Pulmonary (1)
Iron Metabolism Disorders (3) · Metabolic Diseases (3) · Nutritional and Metabolic Diseases (3) · Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Anemia (1) · Anemia, Hemolytic (1) · Anemia, Hemolytic, Congenital (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Genetic Diseases, Inborn (1) · Hemoglobinopathies (1) · Iron Overload (1) · Lung Diseases (1) · Respiratory Tract Diseases (1)
Deferasirox (2) · Deferoxamine (1) · Leflunomide (1)
Novartis Pharmaceuticals (2) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1)
United States (2) · Belgium (1) · Canada (1) · China (1) · France (1) · Germany (1) · Italy (1) · United Kingdom (1)